INSM Reports $306M Q1 Rev, $207.9M BRINSUPRI (+44% QoQ), $98.1M ARIKAYCE (+6% YoY), Reaffirms $1B BRINSUPRI Guidance, $450-470M ARIKAYCE Guidance, ENCORE Study Meets Primary Endpoints, PALM-PAH Study Initiated, sNDA Planned H2 2026
Insmed, Inc. · PHARMACEUTICAL PREPARATIONS · Now $106.03
+10% in 3d after detection
Post-detection moves
1h
—
1d
-3.5%
3d
+10%
7d
+2.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS